[1] |
Fox RI . Sjögren′s syndrome[J]. Lancet, 2005,366(9482):321-331. doi: 10.1016/S0140-6736(05)66990-5.
DOI
URL
PMID
|
[2] |
Li Z, Fu T, Li L , et al. Prevalence, severity, and predictors of dry eye and dry mouth in Chinese patients with primary Sjögren syndrome[J]. Clin Rheumatol, 2018,5(11):2971-2979. doi: 10.1007/s10067-018-4233-9.
|
[3] |
Vivino FB, Bunya VY, Massaro-giordano G , et al. Sjogren′s syndrome: an update on disease pathogenesis, clinical manifestations and treatment[J]. Clin Immunol, 2019,203:81-121. doi: 10.1016/j.clim.2019.04.009.
DOI
URL
PMID
|
[4] |
Both T, Dalm VASH, Hagen PMV , et al. Reviewing primary Sjögren′s syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment[J]. Int J Med Sci, 2017,14(3):191-200. doi: 10.7150/ijms.17718.
DOI
URL
PMID
|
[5] |
van Nimwegen JF, Moerman RV, Sillevis Smitt N , et al. Safety of treatments for primary Sjögren′s syndrome[J]. Expert Opin Drug Saf, 2016,15(4):513-524. doi: 10.1517/14740338.2016.1146676.
DOI
URL
PMID
|
[6] |
Cifuentes M Del Barrio-Díaz P Vera-Kellet C . Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sjögren syndrome: a double-blind randomized controlled trial[J]. Br J Dermatol, 2018,179(5):1056-1061. doi: 10.1111/bjd.16442.
DOI
URL
PMID
|
[7] |
Ma SJ, Rivers CI, Serra LM , et al. Long-term outcomes of interventions for radiation-induced xerostomia: a review[J]. World J Clin Oncol, 2019,10(1):1-13. doi: 10.5306/wjco.v10.i1.1.
DOI
URL
PMID
|
[8] |
Vitali C, Bombardieri S, Jonsson R , et al. Classification criteria for Sjögren′s syndrome: a revised version of the european criteria proposed by the american-european consensus group[J]. Ann Rheum Dis, 2002,61(6):554-558. doi: 10.1136/ard.61.6.554.
DOI
URL
PMID
|
[9] |
Shiboski CH, Shiboski SC, Seror R , et al. 2016 american college of rheumatology/european league against rheumatism classification criteria for primary Sjögren′s syndrome: a consensus and data-driven methodology involving three international patient cohorts[J]. Arthritis Rheumatol, 2017,69(1):35-45. doi: 10.1002/art.39859.
DOI
URL
PMID
|
[10] |
da Mata ADSPD, Amaral JPDAR, Thomson WM , et al. Patient-related outcomes in Sjögren syndrome treated with stimulants of salivary secretion: randomized clinical trial[J]. Oral Dis, 2020,26(2):313-324. doi: 10.1111/odi.13251.
DOI
URL
PMID
|
[11] |
Lacombe V, Lacout C, Lozac′h P , et al. Unstimulated whole saliva flow for diagnosis of primary Sjögren′s syndrome: time to revisit the threshold?[J]. Arthritis Res Ther, 2020,22(1):38. doi: 10.1186/s13075-020-2132-3.
DOI
URL
PMID
|
[12] |
Klinngam W, Janga SR, Lee C , et al. Inhibition of cathepsin s reduces lacrimal gland inflammation and increases tear flow in a mouse model of Sjögren′s syndrome[J]. Sci Rep, 2019,9(1):9559. doi: 10.1038/s41598-019-45966-7.
DOI
URL
PMID
|
[13] |
Applbaum E, Lichtbroun A . Novel Sjögren′s autoantibodies found in fibromyalgia patients with sicca and/or xerostomia[J]. Autoimmun Rev, 2019,18(2):199-202. doi: 10.1016/j.autrev. 2018. 09.004.
DOI
URL
PMID
|
[14] |
Shen L, He J, Kramer JM , et al. Sjögren′s syndrome: animal models, etiology, pathogenesis, clinical subtypes, and diagnosis[J]. J Immunol Res, 2019,2019:8101503. doi: 10.1155/2019/8101503.
DOI
URL
PMID
|
[15] |
Feng H, Qiao J, Ding N , et al. Sjögren′s syndrome complicated by myeloid/natural killer cell precursor acute leukemia: case report and review of the literature[J]. Case Rep Hematol, 2016,2016:8261249. doi: 10.1155/2016/8261249.
DOI
URL
PMID
|
[16] |
Mitoh Y, Ueda H, Ichikawa H , et al. Effects of cevimeline on excitability of parasympathetic preganglionic neurons in the superior salivatory nucleus of rats[J]. Auton Neurosci, 2017,206:1-7. doi: 10.1016/j.autneu.2017.05.010.
DOI
URL
PMID
|
[17] |
Farag AM, Holliday C, Cimmino J , et al. Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation[J]. Oral Dis, 2019,25(8):1937-1944. doi: 10.1111/odi.13192.
DOI
URL
PMID
|
[18] |
Ueda H, Mitoh Y, Ichikawa H , et al. Cevimeline enhances the excitability of rat superior salivatory neurons[J]. J Med Invest, 56(Suppl):267-269. doi: 10.2152/jmi.56.267.
DOI
URL
|
[19] |
Barbe AG . Long-term use of the sialogogue medications pilocarpine and cevimeline can reduce xerostomia symptoms and increase salivary flow in head and neck cancer survivors after radiotherapy[J]. J Evid Based Dent Pract, 2017,17(3):268-270. doi: 10.1016/j.jebdp.2017.06.013.
DOI
URL
PMID
|
[20] |
Ono M, Takamura E, Shinozaki K , et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren′s syndrome: a randomized, double-blind clinical study[J]. Am J Ophthalmol, 2004,138(1):6-17. doi: 10.1016/j.ajo.2004.02.010.
DOI
URL
PMID
|
[21] |
Leung KC, Mcmillan AS, Wong MC . The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren′s syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study[J]. Clin Rheumatol, 2008,27(4):429-436. doi: 10.1007/s10067-007-0723-x.
DOI
URL
|